In 2015, the total output value produced by enterprises above designated size in Hunan's pharmaceutical industry exceeded 100 billion yuan for the first time, as released by the Hunan Economic and Information Technology Commission on Feb. 28.
The added value of pharmaceutical industry in 2015 increased 14.8% year on year to over 30 billion yuan, 5% higher than the national average and 7% higher than the provincial average in this sector. The growth rate ranked first among 11 key industries in Hunan. Hunan's pharmaceutical industry saw 99.75 billion yuan in main business income, ranking 11th in China and accounting for 3.3% of the national total.
The pharmaceutical industry in Hunan has witnessed a significant progress in innovative ability. A batch of key laboratories at national or provincial level and engineering technology centers has been set up in recent five years. Some remarkable achievements won the second prize for national scientific and technological progress, including a diagnosis and treatment system on chronic hepatitis B developed by Sansure Biotech Inc., and medicines mainly for expelling pathogenic wind.
Its core competitiveness has been enhanced. Hunan Er-Kang Pharmaceutical Co., Ltd has become a leading excipient supplier in China. Hunan Kelun Group took the lead in developing a powderquid dual-chamber soft transfusion bags. Sansure Biotech Inc. has obtained a registered certificate granted by the State Food and Drug Administration (SFDA), and 26 CE certificates.
The main business income of Hunan's pharmaceutical industry is expected to exceed 200 billion yuan in 2020, according to the Hunan Economic and Information Technology Commission.
Please refer to www.enghunan.gov.cn when using the article.
Translator: Xiao Juan
Chinese source: hunan.gov.cn